SOLICITATION NOTICE
R -- In vitro efficacy study of new small molecules that target HIV
- Notice Date
- 8/4/2016
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Child Health and Human Development, Contracts Management Branch, 6710B Rockledge Dr., Suite 1124, MSC7000, Bethesda, Maryland, 20892-7510, United States
- ZIP Code
- 20892-7510
- Solicitation Number
- NIH-NICHD-16-141
- Archive Date
- 8/29/2016
- Point of Contact
- Amber Harris, Phone: 3014028778
- E-Mail Address
-
amber.harris@nih.gov
(amber.harris@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NIH-NICHD- 16-141 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2005-78. The North American Industry Classification (NAICS) Code is 325414 and the business size standard is 1,250. The National Institutes of Health (NIH), National Institute of Digestive, Diabetes & Kidney Diseases (NIDDK) intends to award a purchase order to IMQUEST BIOSCIENCES, INC., 7340 Executive Way, Suite R., Frederick, MD 21704. This is pursuant to 41 U.S.C. 253(c)(1)-Only one responsible source and no other supplies or services will satisfy agency requirements. Synthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases has a requirement for in vitro efficacy study of new small molecules that target HIV. This is an ongoing project. The requirement is to screen candidate compounds in CEM-SS cells infected with HIV-1. Plated cells will also be examined for compound toxicity. Compounds will be tested in parallel against control drug AZT. The initial efficacy work was done in 2012. In the interim additional molecules have been designed and synthesized. Substantial data generation was done by the original vendor, ImQuest, this purchase of antiviral testing is a follow-on requirement that must be done by the same company to allow comparison of efficacy and any toxicity. Lab-to-lab variability is inherent in biological testing. To make a responsible purchase and not invalidate the investment already made in the project, the same lab must be used for this additional testing. The risk of using a lab that has no experience of targeting zinc fingers will not be able to interpret the performance. ImQuest has not only compiled the NIDDK's proprietary data, but they are also able to build upon it. This vendor has the done the work and provided the prior results and is the only one who can look at the base results and state that the results meaningful as they will be obtained from the same experimental design and operational procedure. Offers will also be evaluated on best value in relation to price. Offerors who are capable of providing at a minimum, fifty-one percent (51%) of the required/actual services of this solicitation must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of providing the required/actual equipment in this synopsis should submit a copy of their quotation to the below address or via email to amber.harris@nih.gov. Offers must also be accompanied by descriptive literature, delivery timeframe, warranties, and/or other information that demonstrates that the offer meets all of the foregoing requirements. Quotations will be due ten (10) calendar days from the publication date of this synopsis or by August 4, 2016 by 10:00am EST. via email or postal mail. The quotation must reference Solicitation number NIH-NICHD-16-141. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710 Rockledge Drive, Room 1159A, Bethesda, MD 20817 Attention: Amber Harris, by the date and time mentioned above. Any questions must be sent via email to amber.harris@nih.gov and must include Solicitation number NIH-NICHD-16-141 in the subject line of email. Faxed copies/responses will not be accepted. PLEASE NOTE: In order to receive an award, contractor must be registered and have valid certification in the System for Award Management (SAM) http://www.sam.gov.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NICHD/NIH-NICHD-16-141/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04209787-W 20160806/160804235307-9c1cba7a25e38b80c6a8fa8851800f30 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |